Journal article

Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents.

R Hurwitz, R Blackmore, P Hazell, K Williams, S Woolfenden

Cochrane Database of Systematic Reviews Online | WILEY | Published : 2012

Abstract

Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental disorders, ranging in severity and characterised by early onset of delay and deviance in the development of social interaction, and verbal and nonverbal communication. ASD is associated with restricted and/or stereotyped interests or behaviours. Tricyclic antidepressants (TCAs) block noradrenaline and serotonin reuptake, increasing the availability of these neurotransmitters in the central nervous system. Via their impact on serotonin, TCAs have been used in the treatment of autistic symptoms and comorbidities in individuals with ASD.   To determine if treatment with tricyclic antidepressants:1) improves the core..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

Philip Hazell - has worked as a consultant for Eli Lilly and Janssen. He has research contracts with Eli Lilly and Celltech. He is a member of the advisory board of Eli Lilly, Australia; Janssen, Australia; Novartis, Australia and Shire, International. Dr Hazell has given presentations for Eli Lilly, Pfizer, Janssen and Sanofi. He is an investigator in a trial of fluoxetine for autism spectrum disorders.